Literature DB >> 20585114

Serum and cerebrospinal fluid levels of colistin in pediatric patients.

Charalampos Antachopoulos1, Matti Karvanen, Elias Iosifidis, Britt Jansson, Diamantis Plachouras, Otto Cars, Emmanuel Roilides.   

Abstract

Using a liquid chromatography-tandem mass spectrometry method, the serum and cerebrospinal fluid (CSF) concentrations of colistin were determined in patients aged 1 months to 14 years receiving intravenous colistimethate sodium (60,000 to 225,000 IU/kg of body weight/day). Only in one of five courses studied (a 14-year-old receiving 225,000 IU/kg/day) did serum concentrations exceed the 2 microg/ml CLSI/EUCAST breakpoint defining susceptibility to colistin for Pseudomonas and Acinetobacter. CSF colistin concentrations were <0.2 microg/ml but increased in the presence of meningitis (approximately 0.5 microg/ml or 34 to 67% of serum levels).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20585114      PMCID: PMC2935015          DOI: 10.1128/AAC.01799-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis.

Authors:  M E Jiménez-Mejías; C Pichardo-Guerrero; F J Márquez-Rivas; D Martín-Lozano; T Prados; J Pachón
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2002-03-19       Impact factor: 3.267

2.  Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography.

Authors:  Jian Li; Robert W Milne; Roger L Nation; John D Turnidge; Kingsley Coulthard; Jason Valentine
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

Review 3.  Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections.

Authors:  Jian Li; Roger L Nation; John D Turnidge; Robert W Milne; Kingsley Coulthard; Craig R Rayner; David L Paterson
Journal:  Lancet Infect Dis       Date:  2006-09       Impact factor: 25.071

Review 4.  Polymyxins revisited.

Authors:  David Landman; Claudiu Georgescu; Don Antonio Martin; John Quale
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

Review 5.  Antimicrobial agents and the central nervous system.

Authors:  E D Everett; L J Strausbaugh
Journal:  Neurosurgery       Date:  1980-06       Impact factor: 4.654

6.  Penetration of colistin into cerebrospinal fluid.

Authors:  S L Markantonis; N Markou; M Fousteri; N Sakellaridis; S Karatzas; I Alamanos; E Dimopoulou; G Baltopoulos
Journal:  Antimicrob Agents Chemother       Date:  2009-08-24       Impact factor: 5.191

7.  Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria.

Authors:  D Plachouras; M Karvanen; L E Friberg; E Papadomichelakis; A Antoniadou; I Tsangaris; I Karaiskos; G Poulakou; F Kontopidou; A Armaganidis; O Cars; H Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2009-05-11       Impact factor: 5.191

8.  Quantitative analysis of colistin A and colistin B in plasma and culture medium using a simple precipitation step followed by LC/MS/MS.

Authors:  Britt Jansson; Matti Karvanen; Otto Cars; Diamantis Plachouras; Lena E Friberg
Journal:  J Pharm Biomed Anal       Date:  2008-12-24       Impact factor: 3.935

Review 9.  Systemic colistin use in children without cystic fibrosis: a systematic review of the literature.

Authors:  Matthew E Falagas; Evridiki K Vouloumanou; Petros I Rafailidis
Journal:  Int J Antimicrob Agents       Date:  2009-01-24       Impact factor: 5.283

  9 in total
  20 in total

1.  Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration of colistin methanesulfonate.

Authors:  Roberto Imberti; Maria Cusato; Giovanni Accetta; Valeria Marinò; Francesco Procaccio; Alfredo Del Gaudio; Giorgio A Iotti; Mario Regazzi
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

Review 2.  Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children.

Authors:  Kathleen Chiotos; Molly Hayes; Jeffrey S Gerber; Pranita D Tamma
Journal:  J Pediatric Infect Dis Soc       Date:  2020-02-28       Impact factor: 3.164

Review 3.  Intrathecal/intraventricular colistin in external ventricular device-related infections by multi-drug resistant Gram negative bacteria: case reports and review.

Authors:  O Bargiacchi; A Rossati; P Car; D Brustia; R Brondolo; F Rosa; P L Garavelli; F G De Rosa
Journal:  Infection       Date:  2014-04-12       Impact factor: 3.553

Review 4.  Carbapenem-Resistant Gram-Negative Bacterial Infections in Children.

Authors:  David Aguilera-Alonso; Luis Escosa-García; Jesús Saavedra-Lozano; Emilia Cercenado; Fernando Baquero-Artigao
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

5.  Successful management of an outbreak due to carbapenem-resistant Acinetobacter baumannii in a neonatal intensive care unit.

Authors:  Olga Tsiatsiou; Εlias Iosifidis; Aspasia Katragkou; Vasiliki Dimou; Kosmas Sarafidis; Theodoros Karampatakis; Charalampos Antachopoulos; Anagnostina Orfanou; Athanasios Tsakris; Vasiliki Drossou-Agakidou; Emmanuel Roilides
Journal:  Eur J Pediatr       Date:  2014-07-02       Impact factor: 3.183

6.  Impact of p-glycoprotein inhibition and lipopolysaccharide administration on blood-brain barrier transport of colistin in mice.

Authors:  Liang Jin; Jian Li; Roger L Nation; Joseph A Nicolazzo
Journal:  Antimicrob Agents Chemother       Date:  2010-11-29       Impact factor: 5.191

Review 7.  Clinical Pharmacokinetics and Pharmacodynamics of Colistin.

Authors:  Nicolas Grégoire; Vincent Aranzana-Climent; Sophie Magréault; Sandrine Marchand; William Couet
Journal:  Clin Pharmacokinet       Date:  2017-12       Impact factor: 6.447

8.  Minocycline attenuates colistin-induced neurotoxicity via suppression of apoptosis, mitochondrial dysfunction and oxidative stress.

Authors:  Chongshan Dai; Giuseppe D Ciccotosto; Roberto Cappai; Yang Wang; Shusheng Tang; Xilong Xiao; Tony Velkov
Journal:  J Antimicrob Chemother       Date:  2017-06-01       Impact factor: 5.790

Review 9.  Antibiotic Distribution into Cerebrospinal Fluid: Can Dosing Safely Account for Drug and Disease Factors in the Treatment of Ventriculostomy-Associated Infections?

Authors:  Nilesh Kumta; Jason A Roberts; Jeffrey Lipman; Menino Osbert Cotta
Journal:  Clin Pharmacokinet       Date:  2018-04       Impact factor: 6.447

Review 10.  Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.

Authors:  Antonello Di Paolo; Giovanni Gori; Carlo Tascini; Romano Danesi; Mario Del Tacca
Journal:  Clin Pharmacokinet       Date:  2013-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.